1. Home
  2. GBIO vs NOTV Comparison

GBIO vs NOTV Comparison

Compare GBIO & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • NOTV
  • Stock Information
  • Founded
  • GBIO 2016
  • NOTV 1974
  • Country
  • GBIO United States
  • NOTV United States
  • Employees
  • GBIO N/A
  • NOTV N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • NOTV Biotechnology: Pharmaceutical Preparations
  • Sector
  • GBIO Health Care
  • NOTV Health Care
  • Exchange
  • GBIO Nasdaq
  • NOTV Nasdaq
  • Market Cap
  • GBIO 41.2M
  • NOTV 46.7M
  • IPO Year
  • GBIO 2020
  • NOTV 1997
  • Fundamental
  • Price
  • GBIO $5.19
  • NOTV $1.18
  • Analyst Decision
  • GBIO Buy
  • NOTV Strong Buy
  • Analyst Count
  • GBIO 4
  • NOTV 1
  • Target Price
  • GBIO $10.67
  • NOTV $5.00
  • AVG Volume (30 Days)
  • GBIO 66.5K
  • NOTV 354.0K
  • Earning Date
  • GBIO 11-07-2025
  • NOTV 12-02-2025
  • Dividend Yield
  • GBIO N/A
  • NOTV N/A
  • EPS Growth
  • GBIO N/A
  • NOTV N/A
  • EPS
  • GBIO N/A
  • NOTV N/A
  • Revenue
  • GBIO $21,230,000.00
  • NOTV $505,299,000.00
  • Revenue This Year
  • GBIO N/A
  • NOTV $5.64
  • Revenue Next Year
  • GBIO N/A
  • NOTV $5.16
  • P/E Ratio
  • GBIO N/A
  • NOTV N/A
  • Revenue Growth
  • GBIO 61.15
  • NOTV 0.85
  • 52 Week Low
  • GBIO $3.00
  • NOTV $1.12
  • 52 Week High
  • GBIO $25.70
  • NOTV $6.48
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 31.82
  • NOTV 30.06
  • Support Level
  • GBIO $5.10
  • NOTV $1.23
  • Resistance Level
  • GBIO $6.47
  • NOTV $1.43
  • Average True Range (ATR)
  • GBIO 0.26
  • NOTV 0.09
  • MACD
  • GBIO -0.14
  • NOTV -0.02
  • Stochastic Oscillator
  • GBIO 9.49
  • NOTV 8.45

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Share on Social Networks: